Oestrogen receptor β:: what it means for patients with breast cancer

被引：106

作者：

Speirs, V

Carder, PJ

Lane, S

Dodwell, D

Lansdown, MR

Hanby, AM

机构：

[1] Univ Leeds, Mol Med Unit, Leeds, W Yorkshire, England

[2] Univ Leeds, Acad Unit Pathol, Leeds, W Yorkshire, England

[3] Leeds Teaching Hosp NHS Trust, Breast Unit, Leeds, W Yorkshire, England

来源：

LANCET ONCOLOGY | 2004年 / 5卷 / 03期

关键词：

D O I：

10.1016/S1470-2045(04)01413-5

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Oestrogen receptor (ER) a is a well established prognostic marker in breast cancer, and all patients who are ERalpha positive receive tamoxifen as adjuvant endocrine therapy. Although ERalpha predicts a favourable disease outcome, the usefulness of ERbeta as a clinical prognostic marker remains to be defined. Here, we outline the history of both ERs and discuss the implications ERbeta has to patients with breast cancer.

引用

页码：174 / 181

页数：10

共 81 条

[1]

Allred DC, 1998, MODERN PATHOL, V11, P155

[2]

Beatson G.T., 1896, LANCET, V148, P162, DOI DOI 10.1016/S0140-6736(01)72384-7

[3]

Beatson GT., 1896, LANCET, V148, P104, DOI DOI 10.1016/S0140-6736(01)72307-0

[4] A novel human estrogen receptor β:: Identification and functional analysis of additional N-terminal amino acids [J].